Scarica l'app Stockscreener
14.84
2.27%
0.33
Dopo l'orario di chiusura:
14.84
Precedente Chiudi:
$14.51
Aprire:
$14.22
Volume 24 ore:
1.30M
Relative Volume:
0.98
Capitalizzazione di mercato:
$902.74M
Reddito:
$10.00M
Utile/perdita netta:
$-113.63M
Rapporto P/E:
-8.0943
EPS:
-1.8334
Flusso di cassa netto:
$-83.28M
1 W Prestazione:
+8.88%
1M Prestazione:
+10.58%
6M Prestazione:
-36.34%
1 anno Prestazione:
-47.47%
Intervallo 1D:
$14.22
$14.91
Intervallo di 1 settimana:
$13.02
$14.91
Portata 52W:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Nome
Janux Therapeutics Inc
Settore
Industria
Telefono
(858) 751-4493
Indirizzo
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
14.84 | 902.74M | 10.00M | -113.63M | -83.28M | -1.8334 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Iniziato | Stifel | Buy |
| 2025-09-10 | Iniziato | Truist | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-07-11 | Iniziato | Raymond James | Outperform |
| 2024-12-03 | Reiterato | BTIG Research | Buy |
| 2024-12-03 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-22 | Iniziato | Leerink Partners | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-05-30 | Iniziato | Scotiabank | Sector Perform |
| 2024-03-21 | Iniziato | BTIG Research | Buy |
| 2024-03-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Iniziato | Wedbush | Outperform |
| 2022-11-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Janux Therapeutics (NASDAQ:JANX) Raised to "Hold" at Wall Street Zen - MarketBeat
Bristol-Myers Squibb Cancer Moves And Equity Efforts Underpin Valuation Case - finance.yahoo.com
71,016 shares tied to option exercise at JANX (NASDAQ: JANX) disclosed - Stock Titan
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal - The Globe and Mail
Janux nominates development candidate under BMS collaboration - BioWorld MedTech
Bristol Myers Squibb (BMY) Partners with Janux on New Cancer The - GuruFocus
Janux Unveils Development Candidate in Bristol Myers Squibb Partnership, Worth $35M Milestone - Contract Pharma
Janux Therapeutics Expects $35 Million Milestone Payment From Bristol-Myers Squibb - Moomoo
Janux Therapeutics announces development candidate nomination under Bristol Myers Squibb collaboration - MarketScreener
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration - TradingView
Janux Therapeutics, Inc. announced that, under its collaboration with Bristol Myers Squibb, it has officially nominated a development candidate drug. - Bitget
Janux Therapeutics receives $35M milestone from Bristol Myers Squibb - Investing.com
Janux Therapeutics receives $35M milestone from Bristol Myers Squibb By Investing.com - in.investing.com
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment - finance.yahoo.com
Janux Therapeutics (JANX) price target decreased by 11.93% to 54.57 - MSN
Understanding the Setup: (JANX) and Scalable Risk - Stock Traders Daily
Janux reports positive phase 1 results for JANX007 in mCRPC; stock down - MSN
We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely - Moomoo
Janux Therapeutics (NASDAQ:JANX) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Does Janux Therapeutics (NASDAQ:JANX) Show Signs of Market Sensitivity? - Kalkine Media
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
JANX SEC FilingsJanux Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
D-Wave Quantum: Die bittere Wahrheit! - Finanztrends
Advanced Renal Cell Carcinoma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeuti - Barchart.com
The Technical Signals Behind (JANX) That Institutions Follow - Stock Traders Daily
8th T-Cell Engager Therapeutics Summit - inewsource
Precision Trading with Janux Therapeutics Inc. (JANX) Risk Zones - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Veeva Systems (VEEV) and Janux Therapeutics Inc (JANX) - The Globe and Mail
HC Wainwright Expects Higher Earnings for Janux Therapeutics - MarketBeat
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits
JANX PE Ratio & Valuation, Is JANX Overvalued - Intellectia AI
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring The 316.79% Potential Upside - DirectorsTalk Interviews
JANX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Truist cuts Janux Therapeutics stock price target on competition By Investing.com - Investing.com Canada
Truist Securities Adjusts PT on Janux Therapeutics to $80 From $100, Maintains Buy Rating - marketscreener.com
Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating - TipRanks
Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma - Bitget
Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial - Finviz
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives - simplywall.st
Key facts: Janux Therapeutics Receives Strong Buy Ratings; Partners with BMS - TradingView
Janux: Encouraging Early T Cell Engager Data, Broad Pipeline, and Strong Cash Runway Support Buy Rating - TipRanks
Cantor Fitzgerald Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Guggenheim Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Janux Therapeutics, Inc. Q4 Loss Rises - Nasdaq
Janux Therapeutics (NASDAQ:JANX) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Janux Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q4 Revenue $0 - marketscreener.com
Janux Therapeutics Inc Azioni (JANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):